Adil Daud


Oncologist and melanoma specialist
Immunotherapy researcher, history and literature buff

About me

Dr. Adil Daud, an oncologist, specializes in melanoma and other skin cancers. He is co-director of the Melanoma Center. In addition to caring for patients, he directs research to better understand the biology of melanoma and to develop new treatments. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.

Daud earned a medical degree at the Government Medical College, Nagpur. He completed both an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida, for seven years.

Daud has won numerous awards, including a Young Investigator Award from the American Society of Clinical Oncology and selection as a Castle Connolly Top Doctor.

  • Education

    Government Medical College, Nagpur, 1986

  • Residencies

    Indiana University School of Medicine, 1997

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, 2000

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


  • Languages


The future of cancer therapy is here, and it is immunotherapy. And it arrived a lot sooner than expected!

Melanoma & Skin Cancer Program

1825 Fourth Street, Third Floor
San Francisco, CA 94158

Decorative Caduceus

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, ...


Decorative Caduceus

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tu...


Decorative Caduceus

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further e...